<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323425</url>
  </required_header>
  <id_info>
    <org_study_id>XIANJ-14ZD25</org_study_id>
    <nct_id>NCT02323425</nct_id>
  </id_info>
  <brief_title>Effects of Limb Ischemic Postconditioning in Young sICAS</brief_title>
  <acronym>EPIC-sICAS</acronym>
  <official_title>Effects of Upper Limb Ischemic Postconditioning on Collateral Circulation in Young Symptomatic Intracranial Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Science Center of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Health Science Center of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the protective effects of upper limb ischemic&#xD;
      postconditioning on collateral circulationin young symptomatic intracranial atherosclerosis&#xD;
      and the baseline characteristics of trial participants, as an open, randomized controlled,&#xD;
      prospective controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is a common cardia-cerebrovascular disease with high morbidity, disability and&#xD;
      mortality rate. And more and more young patients account for the increasing morbidity. Among&#xD;
      them, Symptomatic intracranial atherosclerotic stenosis（sICAS）is a major cause, especially in&#xD;
      Asians.&#xD;
&#xD;
      Currently, traditional therapeutic methods present reluctant achievements on reducing stroke&#xD;
      recurrence and pose threat on patients'health because of invasive operation and severe side&#xD;
      effects. Therefore, other treatment methods are called for urgently. Remote ischemic&#xD;
      post-conditioning refers to local or distal ischemia treatment after the occurrence of&#xD;
      cerebral ischemia. Prior research has shown that repeatedly ischemic reperfusion have&#xD;
      protective effect on lowering the occurrence rate of ischemic events of patients with carotid&#xD;
      stenosis. However, in-depth research on cerebral protection and correlation with collateral&#xD;
      circulation has not been proven in an open, definitive clinical trial.&#xD;
&#xD;
      Thus, the EPIC-sICAS trial will provide important information on the protective effects of&#xD;
      upper limb ischemic post-conditioning on collateral circulation after cerebral Infarction.&#xD;
      Hopefully to present us a very meaningful way to improve the patient's quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change of Collateral Circulation from Baseline and at 6 months</measure>
    <time_frame>Baseline and at 6 months</time_frame>
    <description>Collateral circulation measured in iconography test: Magnetic Resonance Angiography (MRA)、 Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)、Arterial spin-labeled (ASL) perfusion magnetic resonance、Transcranial Cerebral Doppler (TCD)、single photon emission computed tomography（SPECT） Baseline was defined as the onset of stroke within 48h. A higher score represents better collateral circulation status functioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change of Symptomatic Recovery</measure>
    <time_frame>Baseline and at 14 days, 1 month, 6 months, and 1 year</time_frame>
    <description>Functional test: National Institute of Health stroke scale（NIHSS）scores、Activity of Daily Living Scale (ADL) For NIHSS scores, a lower score represents better functioning. For ADL scores, a higher score represents better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change of serum vascular endothelial growth factor (VEGF) and basic Fibroblast Growth Factor (bFGF) from Baseline and at 10 days.</measure>
    <time_frame>Baseline and at 10 days</time_frame>
    <description>A higher amount represents a better outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Remote Ischemic Postconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>remote ischemic postconditioning（RIPC） treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation twice a day for the total of 180 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in control group will receive foundation treatment. Foundation treatment: including blood vessel expansion、free radical elimination etc during acute phase and aspirin (100-300 mg/d), and atorvastatin (20 mg/d) till the end of the study (180 consecutive days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Remote ischemic postconditioning</intervention_name>
    <description>Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.</description>
    <arm_group_label>Remote Ischemic Postconditioning</arm_group_label>
    <other_name>limb ischemic postconditioning</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 to 45 Years old;&#xD;
&#xD;
          2. Symptomatic intracranial atherosclerotic stenosis (sICAS): cranial CTA/MRA/TCD/DSA&#xD;
             confirm the diagnosis, patients got ischemic stroke or transient ischemic attack in&#xD;
             the brain region supplied by the stenosis artery;&#xD;
&#xD;
          3. National Institutes of Health Stroke Scale(NIHSS) score 0-15&#xD;
&#xD;
          4. Written informed consent was signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Cerebral hemorrhage and other parts of the active bleeding disease;&#xD;
&#xD;
          2. Severe aphasia, unable to express himself;&#xD;
&#xD;
          3. A history of brain tumor, brain trauma, cerebral embolism or other brain lesions;&#xD;
&#xD;
          4. Severe lesions of severe cardiac, liver or kidney disease, malignancy or other&#xD;
             systemic organ dysfunction;&#xD;
&#xD;
          5. Blood Pressure&lt; 90 mmHg/60 mmHg or &gt;200 mmHg/110 mmHg after treatment;&#xD;
&#xD;
          6. Dementia and mental illness;&#xD;
&#xD;
          7. Using angiotensin-converting enzyme inhibitors;&#xD;
&#xD;
          8. A history of major surgery or trauma 4 weeks prior to admission;&#xD;
&#xD;
          9. Without informed consent.&#xD;
&#xD;
        Elimination Criteria：&#xD;
&#xD;
          1. Patients with poor compliance，refuse to take regular treatment and examination;&#xD;
&#xD;
          2. patients' condition get exacerbated, with NIHSS score elevate for more than 4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GuoGang Luo, M.D/Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital Xi'an Jiaotong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xunming Ji, M.D/Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng Wei, Master</last_name>
    <phone>+8613572516964</phone>
    <email>67183723@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GuoGang Luo, M.D/Ph.D</last_name>
    <phone>+8618991232449</phone>
    <email>lguogang@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng Wei, graduate</last_name>
      <phone>+8613572516964</phone>
      <email>67183723@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>GuoGang Luo, M.D/Ph.D</last_name>
      <phone>+8618991232449</phone>
      <email>lguogang@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>GuoGang Luo, M.D/Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>XunMing Ji, M.D/Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>February 1, 2017</last_update_submitted>
  <last_update_submitted_qc>February 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Health Science Center of Xi'an Jiaotong University</investigator_affiliation>
    <investigator_full_name>Meng Wei</investigator_full_name>
    <investigator_title>Director, Clinical Research</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>Remote ischemic postconditioning</keyword>
  <keyword>symptomatic atherosclerotic intracranial arterial stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 4, 2018</submitted>
    <returned>January 10, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

